{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:38:07Z","timestamp":1712968687688},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.nrleng.2021.08.005","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T15:14:14Z","timestamp":1712934854000},"page":"340-344","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice"],"prefix":"10.1016","volume":"39","author":[{"given":"P.","family":"P\u00e9rez-Torre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"L\u00f3pez-Send\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ma\u00f1anes Barral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Parees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fanjul-Arb\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alonso-Canovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Mart\u00ednez Castrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2021.08.005_bib0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","article-title":"Depression and Parkinson's disease: current knowledge","volume":"13","author":"Marsh","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0891988703256053","article-title":"Recognition and treatment of depression in Parkinson's disease","volume":"16","author":"Weintraub","year":"2003","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0140","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and management of neuropsychiatric symptoms in Parkinson's disease","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0145","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"Volpi-Abadie","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0150","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0155","first-page":"196","article-title":"Interaction between monoamine oxidase B inhibitors and selective serotonin reuptake inhibitors","volume":"71","author":"Aboukarr","year":"2018","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","article-title":"Safinamide: a review in Parkinson's disease","volume":"31","author":"Blair","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0165","article-title":"A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial","author":"Abbruzzese","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0170","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/phar.1500","article-title":"Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO)","volume":"34","author":"Panisset","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0175","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/brainsci10030176","article-title":"A Spanish consensus on the use of safinamide for parkinson's disease in clinical practice","volume":"10","author":"Pagonabarraga","year":"2020","journal-title":"Brain Sci"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.genhosppsych.2007.09.007","article-title":"Serotonin syndrome: a complex but easily avoidable condition","volume":"30","author":"Dvir","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0185","article-title":"Spanish expert consensus on the use of safinamide in Parkinson's disease","author":"Valldeoriola","year":"2018","journal-title":"Neurologia"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0195","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2147\/TCRM.S139545","article-title":"Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence","volume":"14","author":"Bette","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Study 016 Investigators Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2165\/00003088-199631060-00004","article-title":"Pharmacokinetic\u2013pharmacodynamic relationship of the selective serotonin reuptake inhibitors","volume":"31","author":"Baumann","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0215","first-page":"15","article-title":"Emergencies and critical issues in Parkinson's disease","volume":"20","author":"Simonet","year":"2020","journal-title":"Pract Neurol"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0220","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10072-018-3272-y","article-title":"Real life evaluation of safinamide effectiveness in Parkinson's disease","volume":"39","author":"Mancini","year":"2018","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0225","first-page":"395","article-title":"Tramadol, pharmacology, side effects, and serotonin syndrome: a review","volume":"18","author":"Beakley","year":"2015","journal-title":"Pain Physician"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0230","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1345\/aph.1Q748","article-title":"Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors","volume":"46","author":"Nelson","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0235","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1345\/aph.1D344","article-title":"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine","volume":"38","author":"Houlihan","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nrleng.2021.08.005_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2018.04.025","article-title":"Tramadol: understanding the risk of serotonin syndrome and seizures","volume":"131","author":"Hassamal","year":"2018","journal-title":"Am J Med"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580824000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580824000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T15:14:25Z","timestamp":1712934865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580824000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2173580824000361"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.08.005","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}